Sandoz has received Science Based Targets initiative validation for its greenhouse gas emissions reduction targets, marking a significant milestone in the global generic medicines leader's decarbonisation strategy. The validation confirms that Sandoz's targets meet the standards set by SBTi, an independent climate action organisation that assesses corporate decarbonisation pathways against the level of action needed to limit global warming. The announcement positions Sandoz alongside a growing cohort of pharmaceutical companies committing to externally verified climate ambitions.

 

The Validated Emission Reduction Targets

 

Under the SBTi-validated framework, Sandoz has committed to reduce emissions from its own operations, covering Scope 1 and Scope 2, by 42 percent by 2030 and by 63 percent by 2035, both measured against a 2024 baseline. These targets establish a clear trajectory for direct operational decarbonisation across the company's manufacturing, logistics and corporate footprint. The dual horizon structure aligns with the standard SBTi pathway, providing both a near-term checkpoint and a longer-term decarbonisation goal.

Sandoz has also committed to ensuring that at least 79 percent of its suppliers by emissions, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2030. This supplier engagement target addresses the Scope 3 emissions that typically represent the largest share of a pharmaceutical company's overall footprint. By linking its own progress to supplier commitments, Sandoz extends climate accountability across its value chain rather than treating it as a purely internal matter.

 

The Sustainability Blueprint and Operational Levers

 

To deliver on its targets, Sandoz has established a sustainability blueprint built around a core set of decarbonisation activities that combine emissions reduction with commercial value creation. The blueprint focuses on improving energy efficiency, increasing renewable energy use, packaging and materials innovation and circularity, optimising and decarbonising logistics, and building supplier partnerships to co-create sustainable solutions. The combination addresses both direct operational emissions and the broader value chain footprint.

The framing of the blueprint reflects a strategic emphasis on decarbonisation as a source of operational efficiency and cost savings rather than as a standalone compliance exercise. Kate Ahern, Head of ESG at Sandoz, said operating sustainably is a key contributor to the company's purpose of pioneering access for patients, framing climate action as a driver of commercial competitiveness as well as environmental performance. This positioning is increasingly common among pharmaceutical companies seeking to align climate strategy with cost discipline in a sector under sustained pricing pressure.

 

Read more: Pandora Adds 5th C Carbon Footprint Label to Lab-Grown Diamonds Cutting Emissions by 90%

 

Progress Since Independence

 

The new commitments build on progress made since Sandoz became an independent company in 2023. Between 2023 and 2025 the company reduced absolute emissions by 3 percent and emissions intensity by 15 percent, demonstrating that operational improvements have already begun to deliver measurable results. The faster reduction in intensity compared with absolute emissions reflects ongoing growth in production volumes alongside efficiency gains.

These early-stage results provide a baseline from which Sandoz must accelerate its rate of reduction substantially to meet the 2030 and 2035 targets. Moving from a 3 percent absolute reduction over two years to a 42 percent reduction by 2030 requires a step change in capital investment, energy sourcing decisions and process optimisation. The challenge is comparable to that faced by other manufacturing-intensive pharmaceutical companies pursuing science-based decarbonisation pathways.

 

Why Supplier Engagement Matters in Pharma

 

The 79 percent supplier coverage target is particularly significant given the structure of pharmaceutical value chains, where active ingredient manufacturing, packaging materials and global logistics typically generate substantial upstream emissions. Without coordinated action across these tiers, even aggressive operational decarbonisation cannot deliver meaningful Scope 3 reductions. The pharmaceutical industry has historically lagged behind other consumer-facing sectors in supplier climate engagement, making this target a meaningful step.

Achieving the supplier coverage goal will require Sandoz to embed science-based target expectations into procurement processes, supplier qualification frameworks and ongoing performance management. It also creates an indirect mechanism for influencing decarbonisation across smaller suppliers that might not otherwise commit to formal SBTi pathways. As more pharmaceutical buyers adopt similar requirements, the cumulative pressure on the supplier base is expected to accelerate Scope 3 progress across the sector.

 

Explore OneStop ESG Marketplace: GHG Accounting

 

Strategic Context for the Pharmaceutical Sector

 

The validation comes at a moment when pharmaceutical companies face growing investor and regulatory pressure to demonstrate credible climate strategies. Healthcare systems in major markets, including the United Kingdom's National Health Service and several European national systems, increasingly factor environmental performance into procurement decisions. Pharmaceutical suppliers with externally validated climate targets are better positioned to meet these expectations than peers relying on internal commitments alone.

Ahern noted that significant progress on sustainability has been made and that the SBTi validation confirms the company's emissions reduction targets are both ambitious and credible. The external validation provides a defensible reference point for investor disclosures, customer engagement and regulatory reporting. As mandatory climate disclosure frameworks expand, having SBTi-validated targets reduces the risk of greenwashing allegations and strengthens the credibility of associated claims.

 

Outlook for Pharmaceutical Decarbonisation

 

Whether Sandoz can deliver on its 2030 and 2035 commitments will depend on its ability to scale operational decarbonisation initiatives, secure renewable energy contracts and drive supplier engagement at the pace implied by the targets. The company will need to combine capital investment in efficiency and clean energy infrastructure with disciplined execution of its supplier engagement programme. Continued progress reporting will be essential for maintaining investor and stakeholder confidence in the trajectory.

The Sandoz announcement reflects a broader trend in the pharmaceutical sector, where SBTi validations are becoming a standard expectation for major manufacturers rather than a differentiator. As more companies in the industry secure validated targets, competitive pressure will likely shift toward execution credibility and disclosure quality. Companies able to combine ambitious targets with credible delivery are positioned to lead the next phase of pharmaceutical sector decarbonisation.

 

Source: Sandoz